Pharmarceutical Report | Product Profiles: Insulin Antidiabetics – Key developers compete for basal insulins market

The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012–13 will alter market dynamics.
Features and benefits

• Understand Datamonitor’s independent appraisal of marketed insulin brands and key pipeline agents indicated for treating type 1 and type 2 diabetes.
• Illustrate how pipeline and marketed insulins compare to one another in terms of clinical and commercial attributes.
• Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
• Understand how marketed insulin brands are positioned in the diabetes treatment algorithm and how they are perceived by prescribers.
• Determine to what extent future insulin therapies satisfy the main clinical unmet needs in the treatment of type 1 and type 2 diabetes.

Highlights
With strong marketing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).
Key patents for blockbuster Lantus will expire from 2014–15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generics, as physicians are expected to be reluctant to introduce potential additional variability into patients’ insulin treatment regimens.

Buy Your Copy of Report @ http://www.reportsnreports.com/reports/159563-product-profiles-insulin-antidiabetics-key-developers-compete-for-basal-insulins-market.html 

Report Details:
Published: April 2012
No. of Pages: 65
Price: Single User License: US $ 7600          Corporate User License: US $ 19000




Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
Published diabetes reports
PRODUCT OVERVIEW
Insulin use in type 1 and type 2 diabetes
Insulin coverage in this report
MARKETED PRODUCT PROFILES
Basal insulin class overview
Lantus (insulin glargine; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Lantus
Clinical and commercial attractiveness
Levemir (insulin detemir; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Levemir
Clinical and commercial attractiveness
Other marketed insulin antidiabetics
Fast-acting insulins
Premixed insulins
PIPELINE PRODUCT PROFILES
Degludec (insulin degludec; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other insulin antidiabetics in development
LY2605541 (Eli Lilly/Boehringer Ingelheim)
Improved basal insulin formulations
Non-injected insulin formulations

Browse all Reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/

Athlete’s Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, “Athlete’s Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Athlete's Foot Therapeutics market. The report identifies the key trends shaping and driving the global Athlete's Foot Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Athlete's Foot Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Athlete's Foot Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Athlete's Foot Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Explore Comprehensive list of Tables & Figures available in the report
Athlete’s Foot Therapeutics Market

Report Details:
Published: February 2012
No. of Pages: 59
Price: Single User License – US$3995 Corporate User License – US$11985

Scope
The report provides information on the key drivers and challenges of the Athlete's Foot Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Athlete's Foot Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Athlete's Foot Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Athlete's Foot Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Athlete's Foot Therapeutics market

Major points covered in Table of Contents of this report include

1 Table of Contents 3
2 Athlete’s Foot Therapeutics - Introduction 7
3 Athlete’s Foot Therapeutics - Market Characterization 12
4 Athlete’s Foot Therapeutics - Competitive Assessment 30
5 Athlete’s Foot Therapeutics - Pipeline Assessment 33
6 Athlete’s Foot Therapeutics - Clinical Trials Mapping 40
7 Athlete’s Foot Therapeutics - Strategic Assessment 46
8 Athlete’s Foot Therapeutics - Future Companies 48
9 Athlete’s Foot Therapeutics - Licensing and Partnership Deals 52
10 Athlete’s Foot Therapeutics - Appendix 53
List of Tables

Browse all Pharmaceutical Research Reports